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Abstract
Background
There have been few large-scale, real world studies in Spain to assess change in pain and
quality of life (QOL) outcomes in cancer patients with moderate to severe pain. This study
aimed to assess changes on both outcomes after 3 months of usual care and to investigate
factors associated with change in QoL.
Patients and methods
Large, multi-centre, observational study in patients with lung, head and neck, colorectal or
breast cancer experiencing a first episode of moderate to severe pain while attending one of
the participating centres. QoL was assessed using the EuroQol-5D questionnaire and pain
using the Brief Pain Inventory (BPI). Instruments were administered at baseline and after 3
months of follow up. Multivariate analyses were used to assess the impact of treatment fac-
tors, demographic and clinical variables, pain and other symptoms on QoL scores.
Results
1711 patients were included for analysis. After 3 months of usual care, a significant improve-
ment was observed in pain and QoL in all four cancer groups (p<0.001). Effect sizes were
medium to large on the BPI and EQ-5D Index and Visual Analogue Scale (VAS). Improve-
ments were seen on the majority of EQ-5D dimensions in all patient groups, though breast
cancer patients showed the largest gains. Poorer baseline performance status (ECOG) and
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the presence of anxiety/depression were associated with significantly poorer QOL out-
comes. Improvements in BPI pain scores were associated with improved QoL.
Conclusion
In the four cancer types studied, pain and QoL outcomes improved considerably after 3
months of usual care. Improvements in pain made a substantial contribution to QoL gains
whilst the presence of anxiety and depression and poor baseline performance status signifi-
cantly constrained improvement.
Introduction
Pain is a common and burdensome symptom in cancer patients [1] with data indicating that
50%–90% will require treatment for pain during the course of their disease [2]. Opioids are
recommended for the management of moderate/severe cancer pain by the World Health
Organization and current guidelines [3, 4] and are recognized as the treatment of choice in
these patients [5]. Despite the importance of adequate pain management, however, studies
show that there is substantial undertreatment of cancer pain [6 Deandrea]. One of the causes
for this undertreatment could be the underuse of pain scales by health professionals in clinical
practice.
Pain is clearly an important, specific outcome to monitor when assessing the results of can-
cer patient management in routine care. Quality of life on the other hand is a broad, multidi-
mensional concept and a very relevant outcome for patients. In terms of monitoring the
broader outcomes of care, studies have shown that health-related quality of life (HRQoL) ques-
tionnaires are a practical tool for this purpose [7]. To date, there have been few large-scale
studies in Spain to describe real world outcomes over time in cancer patients with moderate to
severe pain. Such studies are important because they show how pain outcomes evolve in condi-
tions of usual care, in patients who are usually much more heterogenous than those included
in clinical trials and where the presence of co-morbidites, lifestyle factors, and poly-medication
can all potentially impact results.
Standardised assessment of pain and QOL in routine care can also help to identify
patients who are at risk of poorer outcomes. Previous studies have identified various deter-
minants of QoL in cancer patients including age, pain, appetite loss, fatigue, intestinal func-
tion, performance status, emotional functioning, presence of metastases, and treatment
status [8–10]. However, earlier studies relied largely on cross-sectional data and relatively
few have looked at the association between specific patient and treatment-related variables
and change in QOL.
The C2 study was a large, exploratory study which aimed to assess changes in pain and
QOL in cancer patients with moderate-severe cancer pain after 3 months of usual care and to
investigate factors associated with change in QoL. Changes in pain and QOL were assessed
and estimated using effect sizes and multivariate regression models were constructed to inves-
tigate prognostic variables predicting change in QOL. In this paper, we report results from
four of the most commonly diagnosed cancers (lung, breast, colorectal, and head and neck).
Although the study was performed in Spain, the large number and heterogeneity of patients
included and the investigation of factors contributing to change in pain and QoL outcomes
should mean that the study is relevant to researchers more generally who are interested in pain
and quality of life outcomes in clinical practice in cancer patients.
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Materials and methods
Design
The C2 study was a multi-center, prospective, longitudinal, observational study carried out in
150 oncology units throughout Spain. The present analysis was performed in a subset of the
patients included in the study, i.e. patients with lung, breast, colorectal, or head and neck can-
cer. The C2 study protocol was approved by the Ethics Committee of the coordinating hospital
“Hospital Universitario Puerta de Hierro Majadahonda”, file number 266. All patients pro-
vided written informed consent to participate.
Sample
Patients were eligible for enrolment in the C2 study if they were18 years or older and
experiencing moderate to severe pain (measured using a Numeric Rating Scale, NRS0-104)
for the first time while attending one of the participating oncology units. Patients were
screened consecutively for enrolment during routine clinic visits. The patients included were
predominantly managed in an out-patient setting. Patients were excluded if they had psychiat-
ric or neurological disorders which, in the investigator’s judgement, meant they were unable
to complete the study materials. Patients with stable psychiatric conditions who were able to
complete the study questionnaires were eligible for inclusion.
A total of 2643 patients covering 21 different types of cancer were included in the C2
Study between June 2011 and July 2012. As the aim of the study was to describe pain and
QOL outcomes in a broad cross-section of the patient population with moderate to severe
pain treated in oncology units, a wide range of such centres was included from large teach-
ing hospitals to small country hospitals, and including urban and rural settings in all
regions of Spain. For the purposes of the present analysis, we focussed on the 1711 patients
with lung, head and neck, colorectal, or breast cancer. These were the 4 most prevalent can-
cers in the study population and each represented over 10% of the total sample. Of the 17
cancer types excluded from the present analysis, the most common types were prostate
(n = 222) and pancreas (n = 109) and the least frequent were brain (n = 7) and thyroid
(n = 6).
As the C2 Study was designed as an exploratory study, information on study refusal and
screening rejection rates was not collected though in these types of study in Spain the refusal
rate is normally low. Of the patients included at baseline, 19.5% (488 patients) did not attend
the 3 month visit, most commonly because of loss to follow-up (n = 377, or 77.3% of those
who did not complete the study) and withdrawal of informed consent (n = 74, 15.2%). Thirty-
four patients (7%) were discharged and 2 patients died.
Sample size calculations
Sample size for the C2 study as a whole was calculated based on determining the number of
subjects required to assess the prognostic factors affecting evolution in QOL assessed using the
EQ-5D questionnaire. For the purposes of this study, we defined an improvement in QoL as
an increase30% in EQ-5D Index and we initially considered 17 potential prognostic factors
that meant individuals could be classified into one of 17 different distributions of values for
these variables. After incorporating assumptions regarding the number of patients who would
improve and the proportion of variance in the model that would be explained by the prognos-
tic factors included and using an alpha error of 0.05 and a statistical power of 0.8, the final sam-
ple size for the C2 study as a whole was n = 3,008.
Pain and quality of life outcomes in cancer patients and variables predicting improvement
PLOS ONE | https://doi.org/10.1371/journal.pone.0193233 April 3, 2018 3 / 14
Procedures
Patients were followed for 3 months from study inclusion and made a total of 3 study visits
(baseline, 1 month, and 3 months). Pain and QoL were assessed at baseline and 3 months. The
1 month visit was used to collect data on aspects such as dose changes, intestinal function and
pain, but data on QOL was not collected, so results from this visit are not included in the pres-
ent analysis. Surveys were completed in person during routine clinic visits with support form
health care personnel if needed. Participating centres followed their usual approach to patient
management in all cases.
Measures
Pain was categorised using the original version of the Edmonton Classification System for
Cancer Pain (ECS-CP) [11]. Pain severity and impact were assessed using the short form of the
Brief Pain Inventory (BPI-SF) [12], which was recently validated for use in Spain [13]. The
BPI-SF measures patient perceptions of pain severity and degree of pain interference on daily
functioning and provides sub-scale scores for each dimension ranging from 0 (no pain or
interference) to 10 (maximum pain or interference).
Quality of life was measured using the EQ-5D questionnaire [14] which measures QoL in 5
dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each
dimension has three response levels (no problems, some problems, extreme problems) and
respondents check one level on each dimension to indicate their health ‘today’. A single sum-
mary score (EQ-Index) is provided for each health state defined by the instrument based on
societal values (utility weights). In the present study, we used Spanish utility weights, which
range from -0.0757 for the poorest health state to 1 for the best state [15]. Respondents also
rated their overall health status on a 0–100 visual analogue scale (EQ-VAS) where 0 represents
the worst and 100 the best imaginable health state. Both the EQ-5D and BPI-SF were self-
administered.
Other data collected included age, sex, primary tumour site, functional status (measured
using the Eastern Cooperative Oncology Group performance status [ECOG]), time since diag-
nosis, presence and site of metastases, pain origin (tumour, metastases, antineoplastic treat-
ments, other), intestinal function (measured with the Bowel Function Index–BFI- [16]), and
treatment.
Analysis
Change over time was assessed using paired t-tests or Wilcoxon tests. Effect sizes (ES) were cal-
culated to help interpret the magnitude of change. An ES of 0.20 was considered to represent a
small change, 0.50 a moderate change, and 0.80 a large change [17]. Multivariate regression
models were constructed to analyze the degree to which different prognostic variables pre-
dicted the magnitude of change in overall QOL assessed using the EQ-5D Index. The analysis
was performed for each of the four types of cancer studied. We initially assessed 21 potential
prognostic variables which were initially excluded based on bivariate analyses, using a cut-off
of p>0.2. Variables that remained after bivariate analysis were then included independently in
the regression model using forward and backward stepwise analysis until the final model was
derived. The dependent variable was change on the EQ-5D Index. A further analysis was car-
ried out using multivariate logistic regression to test which factors might be associated with a
patient reporting extreme pain at month 3. The dependent variable was ‘extreme pain’ at
month 3 with age, sex, and ECOG status, presence of neuropathic pain, and emotional distress
at baseline selected as potential independent variables for inclusion in the model. Patients with
any of the 4 types of cancer were included in the analysis. Preliminary bivariate analysis was
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performed to test for association between the independent and dependent variables and only
those independent variables with a p-value of<0.2 for association were included. SPSS (ver-
sion 17) was used for all analyses and results were considered statistically significant at p<0.05.
Results
The demographic, clinical and treatment characteristics of the study population included for
the current analysis are shown in Table 1. In all cancer types, the majority of patients were in
ECOG 0 or 1 (range from 63.2% in colorectal cancer to 75.2% in head and neck cancer).
Almost 70% of patients were on chemotherapy, which was largely palliative, except in head
and neck cancer (72.7% curative).
Change in BPI scores from baseline to 3-month follow-up are shown in Table 2. Across
all groups, the severity summary score improved from an overall mean (SD) of 5.3 (1.6) to
2.3 (1.9) and the interference summary score from 5.2 (2.1) to 2.8 (2.3). All cancer sub-types
showed considerable improvement, with large effect sizes ranging from 1.59 for the colorec-
tal group to 2.13 for head and neck cancer patients on the BPI severity sub-score and from
1.0 for the lung cancer patients to 1.43 for the breast cancer group on the interference sub-
scale.
Changes in QoL are shown in Table 3. All cancer types showed improvements on all dimen-
sions of EQ-5D, though they were particularly marked in breast cancer patients. In all cases,
the greatest improvements were seen on the pain/discomfort dimension of EQ-5D with, for
example, 39.2% of lung cancer patients reporting no pain/discomfort after 3 months of follow-
up compared to only 1.6% at baseline. The reduction in the proportion of patients reporting
extreme pain/discomfort was also notable (e.g. from 42.5% of breast cancer patients at baseline
to only 6.1% at 3 months). Improvements on EQ-5D dimensions were reflected in changes on
the EQ-Index, with improvements ranging from 0.12 points (on a scale from -0.0757 to 1) in
lung cancer patients to 0.25 in breast cancer patients. Similar magnitudes of change were seen
on the EQ-VAS, though interestingly breast cancer patients showed the smallest change there
with a gain of 10.3 points on a scale of 0–100. The changes observed correspond to moderate
to large ES.
The bivariate and stepwise selection process for prognostic variables eliminated 9 of the 21
variables originally tested leading to a total of 12 variables included in the final regression
models, though not all of those were statistically significant for the four cancer types
investigated.
The variables most commonly associated with change in QoL (Table 4) were baseline
ECOG score, change on BPI severity and interference sub-scales, baseline EQ-5D Index score,
and presence of anxiety/depression at both visits. A reduction in BPI scores (i.e. less pain), par-
ticularly on the severity sub-scale, was associated with gains in QOL. On the other hand,
poorer baseline performance status and the presence of self-reported anxiety/depression at
both visits significantly constrained improvement in QoL. The coefficient representing the
EQ-Index at baseline indicates that those with poorer baseline health status generally experi-
enced larger improvements over the study period. Models showed good explanatory power
with adjusted R2 of 0.597, 0.699, 0.644, and 0.815, respectively, for lung, head and neck, colo-
rectal, and breast cancer.
In the logistic regression model to test for factors associated with reporting extreme pain at
month 3, only being in ECOG performance status 3–4 at baseline was statistically significant.
Age and sex were not included in the model as they failed to meet the criterion for inclusion at
the stage of bivariate testing and neuropathic pain and emotional distress at baseline, though
included, were not statistically significant.
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Table 1. Descriptive analysis showing baseline socio-demographic, clinical and treatment characteristics of the study population by cancer type.
Variable Lung
n (%)
706 (41.3)
Head and neck n (%)
363 (21.2)
Colorectal
n (%)
334 (19.5)
Breast
n (%)
308 (18.0)
Socio-demographic
Age, years, mean (SD) [range] 63.3 (10.1)
[33–86]
61.7 (11.7)
[24–88]
66 (11.7)
[25–91]
61 (11.7)
[26–89]
Sex, n (%)
Male 558 (79) 286 (79) 204 (61) 10 (3)
Female 148 (21) 77 (21) 130 (39) 298 (97)
Clinical
Functional status
ECOG0 21 (3) 88 (24.2) 20 (6) 18 (5.8)
ECOG1 434 (61.5) 185 (51) 191 (57.2) 188 (61.0)
ECOG2 218 (30.9) 78 (21.5) 86 (25.7) 87 (28.2)
ECOG3 28 (4) 9 (2.5) 33 (9.9) 15 (4.9)
ECOG4 4 (0.6) 3 (0.8) 2 (0.6) 0 (0)
Time since diagnosis, mean (SD) and [range], in months 8.1 (10.7)
[0–84]
10.5 (19.1)
[0–216]
20.7 (25.7)
[0–204]
50.7 (58)
[0–480]
Metastases 565 (80) 124 (34.2) 257 (76.9) 243 (78.9)
Pain secondary to
Primary tumour 283 (40.1) 191(52.6) 126 (37.7) 32 (10.4)
Metastases 384 (54.4) 44 (12.1) 177 (53.0) 221 (71.8)
Antineoplastic treatment 61 (8.6) 184 (50.7) 41 (12.3) 36 (11.7)
Not related to cancer 70 (9.9) 23 (6.3) 50 (15.0) 42 (13.6)
Edmonton classification system for cancer pain (ECS-CP)
Visceral, bone or soft tissue pain 421 (59.6) 209 (57.6) 228 (68.3) 241 (78.2)
Neuropathic pain, mixed or unknown 210 (29.7) 122 (33.6) 117 (35.0) 142 (46.1)
Incident pain 170 (24.1) 124 (34.2) 84 (25.1) 43 (14.0)
Psychological distress 115 (16.3) 64 (17.6) 67 (20.1) 48 (15.6)
Slow opioid escalation 84 (11.9) 63 (17.4) 56 (16.8) 60 (19.5)
Intestinal function
BFI1 30 518 (73.4) 275 (75.8) 200 (59.9) 227 (73.7)
BFI> 30 159 (22.5) 81 (22.3) 123 (36.8) 64 (20.8)
Treatment
Chemotherapy 512 (72.5) 245 (67.5) 234 (70.1) 201 (65.3)
Palliative 412 (80.5) 66 (26.9) 173 (73.9) 170 (84.6)
Curative 100 (19.5) 178 (72.7) 61 (26.1) 31 (15.4)
Treatment line
1 341 (66.6) 202 (82.4) 126 (53.8) 75 (37.3)
2 126 (24.6) 33 (13.5) 60 (25.6) 68 (33.8)
3 34 (6.6) 7 (2.9) 26 (11.1) 27 (13.4)
> 3 11 (2.1) 2 (0.8) 22 (9.4) 31 (15.4)
Patients receiving radiotherapy at baseline 282 (39.9) 268 (73.8) 96 (28.7) 127 (41.2)
Palliative 198(70.2) 38 (14.2) 52 (54.2) 107 (84.3)
Curative 84(29.8) 230 (85.8) 44 (45.8) 20 (15.7)
Pain treatment (WHO scale) 694 (98.3) 357 (98.3) 334 (100) 306 (99.4)
Step 1: non-opioid+optional adjuvant 363 (52.3) 219 (61.3) 212 (63.5) 157 (51.3)
Step 2: weak opioid + non-opioid + optional adjuvant 96 (13.8) 41 (11.5) 35 (10.5) 41 (13.4)
Step 3: strong opioid + non-opioid + optional adjuvant 548 (79) 287 (80.4) 251 (75.1) 224 (73.2)
(Continued)
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Discussion
In this exploratory study of outcomes in cancer patients treated in usual clinical practice in
Spain, we observed substantial improvements in pain and QOL in the four cancer types stud-
ied. In terms of results on the pain measure (BPI), patients in all 4 groups showed similar mag-
nitudes of improvement on the severity and interference sub-scales. The smallest
improvement on the severity sub-scale was seen in the colorectal group, though the difference
was small (change of 2.7 vs a mean change of 3.1 in the other three groups). All of the changes
correspond to large effect sizes, indicating substantial improvement in pain in all four groups.
As regards QOL, breast cancer patients showed the biggest improvement on the EQ-5D Index,
followed by head and neck, colorectal, and lung cancer patients. Interestingly, the order was
not the same on the EQ-5D VAS, where head and neck patients showed the biggest gains, fol-
lowed by lung, colorectal, and breast cancer patients.
Discrepancies between the EQ-Index and EQ-VAS have been reported previously [18] and
may be due to the fact that whereas the EQ-Index summarises results on the 5 specific health
dimensions in the EuroQol descriptive system, the EQ-VAS asks patients to evaluate their
Table 1. (Continued)
Variable Lung
n (%)
706 (41.3)
Head and neck n (%)
363 (21.2)
Colorectal
n (%)
334 (19.5)
Breast
n (%)
308 (18.0)
Antiemesis/laxatives
Laxative 223 (32.1) 106 (29.7) 124 (37.1) 97 (31.7)
Antiemetic 152 (21.9) 64 (17.9) 108 (32.3) 69 (22.5)
1BFI, Bowel Function Inventory.
https://doi.org/10.1371/journal.pone.0193233.t001
Table 2. Descriptive analysis showing scores on the Brief Pain Inventory by cancer type at baseline and 3 months, means and standard deviations.
Lung Head and neck Colorectal Breast
Baseline 3-month follow-up Baseline 3-month follow-up Baseline 3-month follow-up Baseline 3-month follow-up
Pain severity (0–10)
Maximum pain intensity 7 (1.6) 3.5 (2.5) 7.2 (1.5) 3.3 (2.3) 6.9 (1.8) 3.7 (2.8) 7.0 (1.6) 3.5 (2.2)
Minimum pain intensity 3.7 (2.2) 1.5 (1.6) 3.3 (2.0) 1.1 (1.4) 3.5 (2.1) 1.5 (1.9) 4.4 (2.5) 1.8 (1.8)
Average pain intensity 5.4 (1.6) 2.4 (1.9) 5.3 (1.6) 2.2 (1.8) 5.3 (1.8) 2.4 (2.2) 5.7 (1.8) 2.6 (1.9)
Pain intensity at the time of
completion
5.2 (2.1) 2.0 (2.0) 5.0 (2.1) 1.6 (1.8) 4.8 (2.3) 2.0 (2.2) 5.5 (2.2) 2.3 (1.9)
Severity summary score 5.3 (1.6) 2.3 (1.9) 5.2 (1.5) 2.0 (1.7) 5.1 (1.7) 2.4 (2.1) 5.6 (1.8) 2.5 (1.8)
Pain interference (0–10)
General activity 5.9 (2.3) 3.4 (2.8) 5.4 (2.3) 2.8 (2.4) 6.2 (2.3) 3.5 (3.0) 6.2 (2.1) 3.1 (2.3)
Mood 5.4 (2.5) 3.1 (2.9) 5.7 (2.5) 2.7 (2.4) 5.6 (3.0) 3.4 (3.1) 6.1 (2.5) 2.9 (2.5)
Walking 3.9 (3.0) 2.5 (2.8) 2.0 (2.6) 1.0 (1.7) 4.7 (3.0) 2.7 (2.7) 4.9 (3.0) 2.3 (2.2)
Usual work 5.6 (2.5) 3.4 (2.9) 4.6 (2.9) 2.6 (2.5) 6.1 (2.5) 3.7 (3.2) 6.2 (2.4) 3.1 (2.5)
Relations with others 4.3 (2.7) 2.5 (2.6) 5.0 (2.6) 2.6 (2.5) 4.5 (3.1) 2.6 (2.7) 5.0 (2.8) 2.5 (2.3)
Sleep 4.4 (2.9) 2.1 (2.3) 4.7 (2.9) 2.2 (2.4) 4.7 (3.1) 2.5 (2.6) 5.1 (2.9) 2.2 (2.2)
Enjoyment 5.8 (2.5) 3.5 (3.0) 6.1 (2.3) 3.1 (2.6) 6.4 (2.6) 3.9 (3.2) 6.2 (2.4) 3.0 (2.5)
Interference summary score 5.0 (2.1) 2.9 (2.5) 4.8 (1.9) 2.4 (2.1) 5.5 (2.2) 3.2 (2.7) 5.7 (2.1) 2.7 (2.1)
All baseline to 3 month changes were statistically significant at <0.001 (Wilcoxon test).
https://doi.org/10.1371/journal.pone.0193233.t002
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overall health without reference to any specific dimensions of health. Similarly, the EQ-Index
is calculated using general population utility weights, which could potentially affect results due
to differential weighting by dimension, whilst the VAS is a simple self-rating of the patient’s
health.
Table 3. Results of bivariate analysis showing changes in quality of life (EuroQoL-5D) by cancer type from baseline to 3-month follow-up visit.
Lung
N = 495
Head and neck
N = 315
Colorectal
N = 271
Breast
N = 280
Baseline 3-month
follow-up
P Baseline 3-month
follow-up
p Baseline 3-month
follow-up
p Baseline 3-month
follow-up
p
Dimensions, n
(%)
Mobility
No problems 224
(45.3)
274 (55.4) <0.0011 252
(80.0)
262 (83.2) 0.4691 116
(42.8)
142 (52.4) <0.0011 103
(36.8)
152 (54.3) <0.0011
Some problems 248
(50.1)
177 (35.8) 59 (18.7) 48 (15.2) 135
(49.8)
105 (38.7) 153
(54.6)
120 (42.9)
Confined to bed 23 (4.6) 44 (8.9) 4 (1.3) 5 (1.6) 20 (7.4) 24 (8.9) 24 (8.6) 8 (2.9)
Self-care
No problems 242
(48.9)
294 (59.4) <0.0011 211
(67.0)
222 (70.5) 0.3671 154
(56.8)
161 (59.4) 0.3711 102
(36.4)
182 (65.0) <0.0011
Some problems 234
(47.3)
156 (31.5) 95 (30.2) 87 (27.6) 95 (35.1) 84 (31.0) 145
(51.8)
88 (31.4)
Unable to 19 (3.8) 45 (9.1) 9 (2.9) 6 (1.9) 22 (8.1) 26 (9.6) 33 (11.8) 10 (3.6)
Usual activities
No problems 110
(22.2)
184 (37.2) <0.0011 91 (28.9) 142 (45.1) <0.0011 50 (18.5) 102 (37.6) <0.0011 33 (11.8) 110 (39.3) <0.0011
Some problems 335
(67.7)
235 (47.5) 194
(61.6)
156 (49.5) 164
(60.5)
114 (42.1) 185
(66.1)
148 (52.9)
Unable to 50 (10.1) 76 (15.4) 30 (9.5) 17 (5.4) 57 (21.0) 55 (20.3) 62 (22.1) 22 (7.9)
Pain / discomfort
None 8 (1.6) 194 (39.2) <0.0011 9 (2.9) 125 (39.7) <0.0011 1 (0.4) 115 (42.4) <0.0011 3 (1.1) 122 (43.6) <0.0011
Moderate 337
(68.1)
260 (52.5) 160
(50.8)
169 (53.7) 154
(56.8)
126 (46.5) 158
(56.4)
141 (50.4)
Extreme 150
(30.3)
41 (8.3) 146
(46.3)
21 (6.7) 116
(42.8)
30 (11.1) 119
(42.5)
17 (6.1)
Anxiety/
depression
None 193
(39.0)
250 (50.5) <0.0011 94 (29.8) 175 (55.6) <0.0011 88 (32.5) 128 (47.2) <0.0011 74 (26.4) 160 (57.1) <0.0011
Moderate 269
(54.3)
217 (43.8) 175
(55.6)
120 (38.1) 138
(50.9)
108 (39.9) 166
(59.3)
103 (36.8)
Extreme 33 (6.7) 28 (5.7) 46 (14.6) 20 (6.3) 45 (16.6) 35 (12.9) 40 (14.3) 17 (6.1)
Index score3
mean (SD)
0.51
(0.22)
0.63 (0.29) <0.0012
(0.55)
0.51
(0.21)
0.72 (0.23) <0.0012
(1.0)
0.45
(0.25)
0.61 (0.31) <0.0012
(0.64)
0.41
(0.24)
0.66 (0.22) <0.0012
(1.04)
EQ-5D VAS (0–
100)4
mean (SD)
47.7
(20.0)
59.2 (23.8) <0.0012
(0.58)
49.3
(18.8)
65.7 (18.4) <0.0012
(0.87)
47.1
(20.8)
58.3 (25.9) <0.0012
(0.54)
44.0
(24.2)
54.3 (28.8) <0.0012
(0.43)
1 Chi-square test.
2 Fisher’s exact test.
3 EQ-5D Index score: ranges from -0.0757 (worst health state on EQ-5D descriptive system) to 1 (perfect health).
4 EQ-5D VAS scores ranges from 0 to 100, with higher scores indicating better QoL.
Effect sizes are provided in parenthesis for continuous variables.
https://doi.org/10.1371/journal.pone.0193233.t003
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In regard to the head and neck cancer patients, the majority had pain secondary to the
tumor or to treatment and were receiving curative treatment for localized cancer. Of note,
these patients frequently show acute treatment-related toxicity including moderate to severe
pain from surgery, mucositis related with radiotherapy, and drug-related neurotoxicity [19,
20]. Some of the improvement in pain and QOL observed in these patients may have been due
to withdrawal or completion of radiotherapy over the study period.
While improvements were observed in all four patient groups and in practically all EQ-5D
dimensions, after 3 months of follow-up varying proportions of patients still reported extreme
problems in EQ-5D dimensions. Notably, 15.4% of lung cancer patients and 20.3% of colorec-
tal cancer patients reported being unable to perform their usual activities, 11.1% of colorectal
Table 4. Factors predicting change in QoL measured by the EQ-5D Index: Multivariate regression analyses.
LUNG HEAD AND NECK COLORECTAL BREAST
95% CI 95% CI 95% CI 95% CI
B B p
value
LCI UCI β B p
value
LCI UCI β B P
value
LCI UCI β B p
value
LCI UCI
(Intercept) .319 .000 .172 .467 .543 .000 .426 .661 .285 .001 .121 .450 .378 .000 .192 .563
Sex (ref. female) .072 .043 .025 .006 .081
Time since diagnosis
(months)
.133 .002 .012 .000 .003
ECOG 1 (ref.
ECOG0)
-.184 -.109 .057 -.221 .003 -.142 -.071 .001 -.111 -.031 -.074
ECOG 2 (ref.
ECOG0)
-.213 -.134 .026 -.252 -.016 -.152 -.095 .000 -.147 -.043 -.15
ECOG 3 or 4 (ref.
ECOG0)
-.152 -.188 .012 -.334 -.041 -.077 -.115 .021 -.213 -.018 -.137 -.244 .004 -.411 -.077
Lung metastasis -.104 -.063 .024 -.117 -.008 -.071 -.051 .024 -.096 -.007
Palliative
chemotherapy
.184 .117 .014 .024 .209
Curative
chemotherapy
.123 .140 .028 .015 .266
Line of treatment1 -.246 -.062 .001 -.097 -.026
Anxiety/depression
(EQ-5D dimension2)
-.193 -.116 .000 -.169 -.064 -.279 -.143 .000 -.179 -.108 -.193 -.112 .000 -.173 -.052 -.196 -.117 .000 -.156 -.079
EQ-5D Index at
baseline
.062 -.528 .000 -.650 -.407 -.567 -.683 .000 -.775 -.590 -.376 -.444 .000 -.591 -.296 -.577 -.697 .000 -.800 -.594
Average pain at
baseline
-.192 -.031 .000 -.046 -.016 -.142 -.024 .023 -.044 -.003 -.149 -.024 .001 -.038 -.010
Changes in BPI
severity summary
score
-.479 -.055 .000 -.067 -.044 -.378 -.046 .000 -.059 -.033 -.353 -.045 .000 -.065 -.025 -.257 -.037 .000 -.052 -.022
Changes in BPI
interference
summary score
-.020 .003 -.033 -.007 -.258 -.035 .000 -.048 -.023 -.367 -.052 .000 -.072 -.031 -.318 -.049 .000 -.066 -.033
ECS-CP3 .112 .174 .000 .080 .269
BFI Index4 .087 .001 .030 .000 .002
1Number of lines of treatment (1 = first, 2 = second, 3 = third, 4 = more than third) (reference = 0).
2 Anxiety/depression problems: 1 = present both at baseline and 3 months, 0 = without anxiety/depression problems at least in one visit (ref. = 0).
3 Edmonton: 1 = Poor prognosis; 0 = Good prognosis (ref. = 0).
4BFI Index: Intestinal functioning index (average of ease, sensation and personal judgment) (ref, BPI30, non-altered).
LCI = lower confidence interval; UCI = upper confidence interval.
Empty cells indicate non-statistically significant coefficients in each model.
https://doi.org/10.1371/journal.pone.0193233.t004
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patients still reported extreme pain/discomfort, and 12.9% of the same group reported extreme
anxiety/depression. Patients reporting this level of problem on any EQ-5D dimension would
presumably form a priority group for further investigation and potentially for more concerted
clinical action. In the analysis to test for factors associated with reporting extreme pain at
month 3, only being in ECOG performance status 3–4 at baseline was statistically significant.
This result is coherent as the overall deterioration in health status manifested by the ECOG rat-
ing is associated with more advanced disease or greater morbidity and/or toxicity and part of
that clinical picture would be the presence of higher levels of pain. These results also suggest
that ECOG performance ratings can be used as a prognostic factor. An earlier study by Bradley
et al [21] also found that patients with poorer performance status had significantly higher
symptom distress scores for a range of cancer-related symptoms, though in that case they used
the Karnofsky rating scale.
In terms of the factors associated with change in QoL in all types of cancer, the most rele-
vant were baseline performance status, change on the BPI severity and interference sub-scales,
EQ-5D Index score at baseline, and presence of anxiety/depression at both visits. An earlier
study demonstrated the relationship between improvements in pain as measured by the BPI
and improvements in QoL [22], though that was not performed in cancer patients. The effect
of changes in pain on QoL scores is strong, with the regression analysis suggesting that an
approximately two point change on either the BPI pain severity or pain interference sub-scales
would lead to a change on the EQ-Index which would be close to its minimal important differ-
ence (MID), i.e. the smallest difference in score on a scale which patients perceive as beneficial
[23]. Research in cancer patients has shown that the MID for the EQ-Index ranges from 0.05
to 0.12 when using US and UK utility weights [24].
The regression analysis also showed that the presence of anxiety/depression substantially lim-
ited any gains in QoL. For example, based on the results of that analysis, colorectal cancer
patients reporting anxiety/depression at baseline and at the final visit would have a much smaller
improvement on the EQ-5D Index than those without anxiety/depression. The size of the differ-
ence (0.143 points) indicates that the presence of anxiety/depression likely affects several EQ-5D
dimensions. These results are in line with others reported previously [25] and suggest that appro-
priate management of anxiety and depression in these patients could have substantial benefits in
terms of overall QoL. With respect to the model, there was a degree of construct overlap between
some of the predictor (pain, anxiety/depression) and outcome variables, i.e. between pain and
anxiety/depression in the first case and QOL assessed using EQ-5D, which has pain/discomfort
and anxiety/depression as two of its dimensions, in the second case. This could have affected the
modelling results due to the potential for correlation, though the predictor variables were used as
point assessments while the outcome variable was change on the EQ-5D Index.
Previous studies looking at predictors of QoL in head and neck cancer patients found that
the presence of a feeding tube had the most negative impact on QoL, followed by medical
comorbid conditions, presence of a tracheotomy tube, chemotherapy, and neck dissection.
Hospital site, age, education level, sex, race, and marital status were also significant predictors
of QoL [26]. Clinical predictors of pain included pre-treatment pain score, lower levels of edu-
cation, neck dissection, feeding tube, xerostomia, depressive symptoms, taking more pain
medication, less physical activity, and poor sleep quality [27]. Major predictors of change in
the QOL of head and neck cancer patients from baseline to 1 year included depressive symp-
toms, alongside factors such as feeding tube placement, chemotherapy, and radiation therapy,
as well as baseline smoking [28].
Although we also found that presence of anxiety/depression was a predictor of smaller
improvements in QOL in all patient types, we only found that treatment factors (chemother-
apy) were predictive of change in QOL in the colorectal patients. It is of course possible that
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withdrawal of chemotherapy from some patients over the study period could have influenced
results, as chemotherapy can be associated with pain, though other studies have shown that
chemotherapy can help to alleviate the pain caused by the tumour itself [29–32]. In the present
study, we did not include an assessment of treatment side effects, though that could be of inter-
est in future studies of this type.
Likewise, the present study was not intended to explore change in pain and QoL outcomes
associated with specific treatment patterns, rather it was intended to provide an overall picture
of change in pain and QoL outcomes achieved in routine clinical care, in a wide variety of clin-
ical and geographical settings and including curative and palliative treatment with chemo- or
radiotherapy. It also provides information regarding the proportion of patients who may still
report extreme pain after 3 months of usual care as well as the proportion of patients who are
likely to need treatment for anxiety and depression, which can be useful for planning care.
Strengths of the present study include the large sample size and the fact that patients were
included from a total of 150 oncology units in a mix of settings from all regions of Spain.
While it is not possible to ascertain how representative the sample is, its size and heterogeneity
as well as the fact that it was drawn from Oncology Departments and pain clinics and therefore
reflects the integrated management of patients with cancer, should provide a robust profile of
pain and QOL outcomes for these patients in conditions of usual clinical practice.
Limitations of the study include the relatively short follow-up period and the fact that we
did not collect information on all potentially relevant variables, such as educational level, sleep-
ing, drinking or smoking, for inclusion in the regression models. In the present analysis, we
also did not use the data collected at the one month visit. However, for practical reasons it was
necessary to limit the number of study variables collected and those analysed for this paper.
Another limitation is the fact that we did not perform an analysis of drop-outs from the study,
which could be considered in future studies of this type. It should also be noted that some cor-
relation between measures used in the study is bound to occur, as the EQ-5D already contains
a pain dimension, so it would be surprising if improvements on the BPI did not to a certain
extent predict improvements on the EQ Index. However, pain/discomfort is only one of the
dimensions of EQ-5D and, as shown in Table 3, improvements on other dimensions were also
observed. Likewise, the regression analysis indicates that other factors, not just improvement
in pain, also play a role in the size of the QOL improvement observed.
In conclusion, we found that after 3 months of usual care in oncology units QoL and pain
improved overall in patients with different types of cancer and moderate or severe pain at base-
line, though results varied to some extent by cancer type. Improvements in QoL were associ-
ated with improvements in pain, whilst poor baseline performance status and the presence of
anxiety and depression over the study period severely limited improvements in QoL. The
study results provide an overall picture of change on relevant outcomes in routine clinical care
in these patient groups in Spain and can provide a reference point to reflect on how such out-
comes could be further improved in the future.
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